Literature DB >> 20924294

A prospective randomized trial comparing epidural morphine through intraoperatively placed epidural catheter and intravenous morphine in major lumbar spinal surgery.

Thavat Prasartritha1, Sombat Kunakornsawat, Rachata Tungsiripat, Jaruat Jampa, Roongnapa Throngnumchai.   

Abstract

STUDY
DESIGN: A randomized, controlled trial.
OBJECTIVE: To compare the efficacy of pain control and complications between patients utilizing continuous infusion epidural morphine versus intravenous morphine in posterior spinal surgery. SUMMARY OF BACKGROUND DATA: Recently, there has been increased interest in the use of epidural infusion analgesia for spinal surgery. By simply placing the tip of catheter at the level of operation before the wound closure, a continuous infusion of local anesthetics is directly delivered into the epidural space. Techniques used in the literature vary as per analgesic agents, number of catheters, and the infusion method. Few are the randomized control studies.
METHODS: A total of 120 patients, who had posterior spinal operations, were randomly assigned to receive either continuous epidural infusion morphine, continuous epidural infusion morphine with Bupivacaine, or intravenous morphine as a postoperative analgesia. Visual analogue Pain scale (Pain VAS) was evaluated every 4 hours the first day, and at 36 and 48 hours postoperatively. Additional doses of intravenous Nalbuphine hydrochloride, complications, and the satisfaction score were recorded.
RESULTS: Baseline characteristics of the 3 groups were similar. The mean Pain VAS in the epidural morphine group (groups 1 and 2) were less than that of group 3 at all times up to 48 hours postoperatively (P<0.05). Pain VAS for group 1 was more than that of group 2 at the 16- and 24-hour marks (P<0.05). Pruritus was a common complication in the epidural morphine group. There was no respiratory depression in this study. Patients in groups 1 and 2 had a high proportion of excellent and very good satisfaction (70% to 80%).
CONCLUSION: Epidural infusion analgesia is safe and effective for posterior spinal surgery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20924294     DOI: 10.1097/BSD.0b013e3181cd3048

Source DB:  PubMed          Journal:  J Spinal Disord Tech        ISSN: 1536-0652


  6 in total

1.  Regional anaesthesia and postoperative analgesia techniques for spine surgery - a review.

Authors:  Najoua Mokraï Benyahia; Ann Verster; Vera Saldien; Margaretha Breebaart; Luc Sermeus; Marcel Vercauteren
Journal:  Rom J Anaesth Intensive Care       Date:  2015-04

2.  Pharmacological strategies to reduce pruritus during postoperative epidural analgesia after lumbar fusion surgery - a prospective randomized trial in 150 patients.

Authors:  Eva Gulle; Carola Skärvinge; Karin Runberg; Yohan Robinson; Claes Olerud
Journal:  Patient Saf Surg       Date:  2011-05-14

3.  Nalbuphine for analgesia after fracture surgery and its effect on circulating inflammatory factors.

Authors:  Yong Gong; Yang Zhang; Shoujun Tao
Journal:  Exp Ther Med       Date:  2017-11-06       Impact factor: 2.447

4.  A comparison of the postoperative analgesic efficacy between epidural and intravenous analgesia in major spine surgery: a meta-analysis.

Authors:  Yichen Meng; Heng Jiang; Chenglin Zhang; Jianquan Zhao; Ce Wang; Rui Gao; Xuhui Zhou
Journal:  J Pain Res       Date:  2017-02-14       Impact factor: 3.133

5.  Pathway for enhanced recovery after spinal surgery-a systematic review of evidence for use of individual components.

Authors:  Ana Licina; Andrew Silvers; Harry Laughlin; Jeremy Russell; Crispin Wan
Journal:  BMC Anesthesiol       Date:  2021-03-10       Impact factor: 2.217

6.  Efficacy of gelatin sponge impregnated with ropivacaine on postoperative pain after transforaminal lumbar interbody fusion: a comparative study.

Authors:  Shanxi Wang; Bo Wang; Xiaojun Yu; Tian Ma; Mubotu C Ntambale; Jiyuan Yan; Qing Ding; Ruizhuo Zhang; Hua Wu; Chaoxu Liu
Journal:  BMC Musculoskelet Disord       Date:  2021-08-06       Impact factor: 2.362

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.